Loading clinical trials...
Loading clinical trials...
Double-Blind, Placebo-Controlled Trial of Ondansetron for the Treatment of Cocaine Dependence
The purpose of this study is to assess the efficacy and safety of ondansetron to reduce cocaine use in subjects with cocaine dependence.
Double-blind, placebo-controlled, 4-parallel group design to assess the efficacy and safety of 3 wide range doses of ondansetron to reduce cocaine use in subjects with cocaine dependence and to determine the optimal dose of ondansetron.
Age
18 - 99 years
Sex
ALL
Healthy Volunteers
No
University of Texas Hlth Sci Ctr San Ant
San Antonio, Texas, United States
Start Date
May 1, 2001
Completion Date
December 1, 2002
Last Updated
January 12, 2017
60
Estimated participants
Ondansetron
DRUG
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03606473